New faster and simpler point-of-care test for rapid diagnosis of malaria developed

Written By :  Dr. Kamal Kant Kohli
Published On 2024-03-05 21:15 GMT   |   Update On 2024-03-06 08:09 GMT

USA: The researchers from Rice University in Texas, US, have developed a rapid, accurate test that could be a game changer for diagnosing malaria, especially in areas with limited access to healthcare facilities.The test, which is significantly faster and easier to use than traditional tests, can help healthcare providers quickly identify and treat severe cases, potentially saving lives....

Login or Register to read the full article

USA: The researchers from Rice University in Texas, US, have developed a rapid, accurate test that could be a game changer for diagnosing malaria, especially in areas with limited access to healthcare facilities.

The test, which is significantly faster and easier to use than traditional tests, can help healthcare providers quickly identify and treat severe cases, potentially saving lives. By enabling early detection and appropriate management of malaria cases, the disease burden can be reduced and can improve patient outcomes in Africa and beyond. 

The work is published in the journal Biosensors and Bioelectronics.

Malaria remains a significant global health challenge with an estimated 247 million cases and more than 600,000 deaths annually, the majority of which occur in sub-Saharan Africa. The most severe form, cerebral malaria, has a high mortality rate, particularly in children under 5 years of age.

Current rapid diagnostic tests (RDTs) for malaria provide only a binary result-positive or negative-often missing asymptomatic infections and lacking the sensitivity needed to detect severe cases early. Molecular assays, while more sensitive, are expensive, time-consuming and require specialized equipment and trained personnel, making them impractical for widespread use in resource-limited settings.

To address these challenges, a team led by mechanical engineer Peter Lillehoj of Rice’s Brown School of Engineering, created a microfluidic point-of-care (mPOC) immunoassay for quantifying a malaria parasite biomarker, Plasmodium falciparum histidine-rich protein 2 (PfHRP2), in whole blood.

The device features two diagnostic modes for detecting PfHRP2 at low and high concentrations, making it useful for various diagnostic applications, including the detection of asymptomatic infection and the prediction of disease outcomes. Test results are available in just 15 minutes and can be accessed on a smartphone app, developed by the research team.

“The mPOC immunoassay was designed to be simple, accurate and field-deployable, making it suitable for use in rural and remote health centers in sub-Saharan Africa,” said Lillehoj, associate professor of mechanical engineering. “Unlike traditional tests, this device does not require plasma separation, pipetting, complicated sample processing or long incubations, making it easy to use even by minimally trained health care providers.”

In testing conducted in Malawi, the mPOC immunoassay demonstrated similar accuracy to a commercial PfHRP2 enzyme-linked immunosorbent assay (ELISA) test, while being 12 times faster and simpler to use. The ability to quickly and accurately diagnose malaria, particularly cerebral malaria, at the point of care could lead to early identification and treatment of severe cases, according to Lillehoj.

“In areas with limited access to health care facilities, our test could be a game-changer,” he said. “It can help health care providers quickly identify and treat severe cases, potentially saving lives. By enabling early detection and appropriate management of malaria cases, we can reduce the burden of the disease and improve patient outcomes in Africa and beyond.”   

Reference:

Li J, Saidi AM, Seydel K, Lillehoj PB. Rapid diagnosis and prognosis of malaria infection using a microfluidic point-of-care immunoassay. Biosens Bioelectron. 2024 Apr 15;250:116091. doi: 10.1016/j.bios.2024.116091.

Tags:    
Article Source : Biosensors and Bioelectronics

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News